Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146094
Status:
COMPLETED
Last Update Posted:
2011-08-30
First Post:
2005-09-02
Brief Title:
Bone Mineral Density BMD in HIV Infection
Sponsor:
University Hospital Strasbourg France
Organization:
University Hospital Strasbourg France
Study Overview
Official Title:
Osteopenia and Osteoporosis in HIV Infection Prospective BMD Measurement in Antiretroviral ARV Treated and Untreated HIV-1 Infected Patients
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Osteopenia and osteoporosis are increasingly reported in HIV-infected patients and appear to be more frequent than in general population However pathogenesis remains unclear and published studies still give non concordant results
We therefore started a prospective study to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis BMD evolution over a 2-years period of follow-up will be compared between patients starting ARV therapy and subjects without HAART no indication of treatment A correlation between BMD and several factors will be looked at see below
This study with individual direct benefice is conducted in 3 outpatients clinics Strasbourg Colmar Mulhouse in collaboration with the rheumatologic teams 60 patients are planned to be included over a 3-years inclusion period
We therefore started a prospective study to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis BMD evolution over a 2-years period of follow-up will be compared between patients starting ARV therapy and subjects without HAART no indication of treatment A correlation between BMD and several factors will be looked at see below
This study with individual direct benefice is conducted in 3 outpatients clinics Strasbourg Colmar Mulhouse in collaboration with the rheumatologic teams 60 patients are planned to be included over a 3-years inclusion period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None